Literature DB >> 28237197

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.

Louis P Garrison1, Sachin Kamal-Bahl2, Adrian Towse3.   

Abstract

This commentary identifies and defines potentially useful expansions to traditional cost-effectiveness analysis as often used in health technology assessment. Since the seminal 1977 article by Weinstein and Stason, the recommended approach has been the use of the incremental cost-effectiveness ratio based on the metric of the cost per quality-adjusted life-year gained, allowing comparisons across different technologies. An expanded framework, incorporating a wider range of the elements of value, is proposed. In addition to the core value drivers of health gain and other health system cost savings (if any), we propose adding other less recognized elements related to the value of knowing and informational externalities. We describe each of five factors related to the value of knowing: 1) a reduction in uncertainty, reflecting the benefit of a companion diagnostic increasing the certainty of a patient׳s response to a medicine; 2) insurance value related to greater peace of mind due to protection against catastrophic health and financial loss; 3) the value of hope for a "cure," leading individuals to become risk seekers in some circumstances; 4) real option value due to life extension opening possibilities for individuals to benefit from future innovation; and 5) spillovers or externalities arising from benefits of scientific advances that cannot be entirely appropriated by those making the advances. Further thought and research are needed on how best to measure and integrate these elements into an incremental value framework and on coverage and pricing decisions.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cost; cost-effectiveness analysis; value frameworks; value of knowing

Mesh:

Year:  2017        PMID: 28237197     DOI: 10.1016/j.jval.2016.12.005

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  18 in total

1.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.

Authors:  Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

2.  Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

Authors:  Pengxiang Li; Jordan Jahnke; Amy R Pettit; Yu-Ning Wong; Jalpa A Doshi
Journal:  JAMA Netw Open       Date:  2019-06-05

Review 3.  The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.

Authors:  Elina Eleftheria Pliakos; Nikolaos Andreatos; Fadi Shehadeh; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2018-05-30       Impact factor: 26.132

4.  Assessing potential cures: are there distinctive elements of value beyond health gain?

Authors:  Saskia Hendriks; Steven D Pearson
Journal:  J Comp Eff Res       Date:  2021-03-05       Impact factor: 1.744

5.  Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Authors:  J Jaime Caro; John E Brazier; Jonathan Karnon; Peter Kolominsky-Rabas; Alistair J McGuire; Erik Nord; Michael Schlander
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

Review 6.  How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.

Authors:  Baudouin Standaert; Christophe Sauboin; Rodrigo DeAntonio; Alen Marijam; Jorge Gomez; Lijoy Varghese; Sharon Zhang
Journal:  J Mark Access Health Policy       Date:  2020-01-31

Review 7.  Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics.

Authors:  Louis P Garrison; Adrian Towse
Journal:  J Pers Med       Date:  2017-09-04

8.  The Future of Precision Medicine: Potential Impacts for Health Technology Assessment.

Authors:  James Love-Koh; Alison Peel; Juan Carlos Rejon-Parrilla; Kate Ennis; Rosemary Lovett; Andrea Manca; Anastasia Chalkidou; Hannah Wood; Matthew Taylor
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

9.  Cost-effectiveness of precision medicine: a scoping review.

Authors:  Miriam Kasztura; Aude Richard; Nefti-Eboni Bempong; Dejan Loncar; Antoine Flahault
Journal:  Int J Public Health       Date:  2019-11-15       Impact factor: 3.380

10.  A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT® Re-usable in the Nordics and Benelux.

Authors:  Gustaf Ortsäter; Fredrik Borgström; Stéphane Soulard; Carolin Miltenburger
Journal:  Adv Ther       Date:  2019-10-17       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.